ReviewInternational journal of molecular sciences2023

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.

Linnea Højer Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.